Employees: 03 (2023.0)Legal category: 5785Size: PMECreation date: 2003-07-21 (22 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: RIANS (83560), Var
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELAS PHARMACIE POMAREDE GANCI is a French company
founded 22 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in RIANS (83560),
this company of category PME
shows in 2023 a revenue of 2.8 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELAS PHARMACIE POMAREDE GANCI (SIREN 449452895)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
2 838 693 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
123 718 €
127 857 €
163 268 €
150 846 €
105 142 €
115 325 €
105 876 €
107 563 €
102 666 €
EBITDA
N/C
139 687 €
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
4.5%
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELAS PHARMACIE POMAREDE GANCI generates positive net income of 124 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 103 k€ -> 124 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
123 718 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 8%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 65%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
8.156%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
22.991
15.379
15.748
12.286
14.5
13.592
15.115
11.961
8.156
Financial autonomy
66.009
65.986
63.916
66.379
66.019
68.426
63.627
63.467
64.512
Repayment capacity
None
None
None
None
None
None
None
1.415
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
4.385%
None%
Sector positioning
Debt ratio
8.162024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Excellent
In 2024, the debt ratio of SELAS PHARMACIE POMAREDE ... (8.16) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
64.51%2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Good
In 2024, the financial autonomy of SELAS PHARMACIE POMAREDE ... (64.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Repayment capacity
1.42 years2023
2023
Q1: 0.95 years
Med: 3.58 years
Q3: 7.48 years
Good
In 2023, the repayment capacity of SELAS PHARMACIE POMAREDE ... (1.42) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 83.10. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
69.074
57.274
69.193
62.505
68.746
75.88
97.128
86.945
83.101
Interest coverage
None
None
None
None
None
None
None
2.921
None
Sector positioning
Liquidity ratio
83.12024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Watch
In 2024, the liquidity ratio of SELAS PHARMACIE POMAREDE ... (83.10) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
Interest coverage
2.92x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Good
In 2023, the interest coverage of SELAS PHARMACIE POMAREDE ... (2.9x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELAS PHARMACIE POMAREDE GANCI
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
0 €
111 277 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
0
18
0
Customer payment term (days)
0
0
0
0
0
0
0
4
0
Supplier payment term (days)
0
0
0
0
0
0
0
81
0
Positioning of SELAS PHARMACIE POMAREDE GANCI in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELAS PHARMACIE POMAREDE GANCI is estimated at
1 727 194 €
(range 1 202 791€ - 2 583 982€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1202k€1727k€2583k€
1 727 194 €Range: 1 202 791€ - 2 583 982€
NAF 5 année 2024
Valuation method used
Net Income Multiple
123 718 €
×
14.0x
=1 727 195 €
Range: 1 202 791€ - 2 583 982€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELAS PHARMACIE POMAREDE GANCI with other companies in the same sector:
Frequently asked questions about SELAS PHARMACIE POMAREDE GANCI
What is the revenue of SELAS PHARMACIE POMAREDE GANCI ?
The revenue of SELAS PHARMACIE POMAREDE GANCI in 2023 is 2.8 M€.
Is SELAS PHARMACIE POMAREDE GANCI profitable?
Yes, SELAS PHARMACIE POMAREDE GANCI generated a net profit of 124 k€ in 2024.
Where is the headquarters of SELAS PHARMACIE POMAREDE GANCI ?
The headquarters of SELAS PHARMACIE POMAREDE GANCI is located in RIANS (83560), in the department Var.
Where to find the tax return of SELAS PHARMACIE POMAREDE GANCI ?
The tax return of SELAS PHARMACIE POMAREDE GANCI is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELAS PHARMACIE POMAREDE GANCI operate?
SELAS PHARMACIE POMAREDE GANCI operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart